LifeTech Capital Raises StemCells PT to $8, Maintains Strong Speculative Buy

LifeTech Capital raised its StemCells STEM STEMD price target from $1.60 to $8 and maintained its Strong Speculative Buy rating in a research report published today. In the report, LifeTech Capital states, "StemCells Inc. executed a 1:10 reverse split on July 6th and will trade under the symbol STEMD for the next 20 trading days. While the split-adjusted price will be attractive to institutions, we believe there could be an offsetting decrease in trading liquidity."
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorAnalyst RatingsBiotechnologyHealth CareLifeTech Capital
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!